

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee 1. Trinity Health - Michigan d/b/a St. Mary Mercy Hospital 2. 36475 W. Five Mile Road Livonia, MI 48154		In accordance with letter dated December 5, 2016, 3. License number: 21-14849-01 is amended in its entirety to read as follows:	4. Expiration Date: July 31, 2024 5. Docket No.: 030-08159 Reference No.:
6. Byproduct, source, and/or special nuclear material A. Any byproduct material permitted by 10 CFR 35.100 B. Any byproduct material permitted by 10 CFR 35.200 C. Any byproduct material permitted by 10 CFR 35.300 D. Iridium-192 permitted by 10 CFR 35.400	7. Chemical and/or physical form A. Any B. Any C. Any D. Sealed Sources (Best Medical International, Model 81-01)	8. Maximum amount that licensee may possess at any one time under this license A. As Needed B. As Needed C. 2 curies total, not to exceed 1 curie of iodine-131 D. 1 curie total	9. Authorized use A. For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100. B. For use in imaging and localization studies permitted by 10 CFR 35.200. C. For any diagnostic study or therapy procedure permitted by 10 CFR 35.300. D. For any manual brachytherapy procedure permitted by 10 CFR 35.400.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
21-14849-01Docket or Reference Number
030-08159

Amendment No. 60

6. Byproduct, source,
and/or special nuclear
materialE. Iodine-125 permitted by
10 CFR 35.400F. Palladium-103 permitted
by 10 CFR 35.400G. Cesium-131 permitted by
10 CFR 35.400H. Any byproduct material
permitted by 10 CFR
31.11

7. Chemical and/or physical form

E. Sealed Sources (Bard
Brachytherapy, Model
STM-1251; Best Medical
International, Model 2301;
IsoAid, LLC., Model IAI-125A
(Advantage I-125);
Medi-Physics, Inc., Model 6733
(EchoSeed); North American
Scientific, Model MED3631)F. Sealed Sources (Best Medical
International, Model 2335; North
American Scientific, Model
MED3633; Theragenics, Model
TS200)G. Sealed Sources (IsoRay, Model
CS-1)

H. Prepackaged Kits

8. Maximum amount that licensee
may possess at any one time
under this license

E. 1 curie total

F. 1 curie total

G. 1 curie total

H. 2 millicuries total

9. Authorized use

E. For any manual brachytherapy
procedure permitted by 10 CFR 35.400.F. For any manual brachytherapy
procedure permitted by 10 CFR 35.400.G. For any manual brachytherapy
procedure permitted by 10 CFR 35.400.

H. For use in in-vitro studies.

CONDITIONS

10. Licensed material may be used or stored at the licensee's facilities located at:

1. 36475 West Five Mile Road, Livonia, Michigan, 48154

11. The Radiation Safety Officer (RSO) for this license is Oneil Lee, M.D., Ph.D.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
21-14849-01

Amendment No. 60

Docket or Reference Number
030-08159

12. Licensed material shall only be used by, or under the supervision of:

A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14.

B. The following individuals are authorized users for the material and medical uses as indicated:

Authorized User(M.D.,D.O.,etc.)Material and Use

Karen Lee Johnson-Haddlesey, M.D.	10 CFR 35.100, and 35.200.
Nader Mohtadi, M.D.	10 CFR 35.100, 35.200, and 35.300.
Stephanie E. Falbo, M.D.	10 CFR 35.100, 35.200, and 35.300.
Christopher Markus Esshaki, M.D.	10 CFR 35.100, and 35.200.
George Henning, M.D.	10 CFR 35.300, and 35.400.
Samir Narayan, M.D.	10 CFR 35.400.
Walter M. Sahjidak, M.D.	10 CFR 35.300, and 35.400.
Sean Theisen, M.D.	10 CFR 35.100, and 35.200.
James Paul Carl, M.D.	10 CFR 35.100, 35.200, and 35.300.
Oneil Lee, M.D., Ph.D.	10 CFR 35.100, 35.200, and 35.300.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
21-14849-01

Amendment No. 60

Docket or Reference Number
030-08159

13. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

A. Application dated February, 2014 (ML14037A449)



FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date: February 9, 2017By: Jennifer L. BishopJennifer L. Bishop
Region 3